Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Sanofi SWOT and PESTLE Analysis

ID : 52435853| Jul 2018| 15 pages

COMPANY PROFILE -Sanofi

Business Sector :Pharmaceuticals

Operating Geography :France, Europe, Global

About Sanofi :

Sanofi Corporation was incorporated in 1994 as a société anonyme, a form of limited liability company, for a term of 99 years. In 2004, after a merger with Aventis, it operated under name Sanofi-Aventis until 2011.Since May 2011, it has operated under the commercial name “Sanofi”. Sanofi is a leading global healthcare company, fifth largest pharmaceutical company globally by sales, focused on therapeutic solutions. Sanofi has three principal activities: Pharmaceuticals, Consumer Healthcare (CHC) and Vaccines via Sanofi Pasteur. Sanofi sells prescription drugs mainly to wholesale drug distributors and rare disease products are also sold directly to physicians.

Sanofi Revenue :


€ 35.05 billion (FY ended December 31st, 2017)
€ 33.82 billion (FY ended December 31st, 2016

Ownership / Major shareholders :

L’Oréal 9.43% (Voting rights 16.95%), BlackRock 5.68% (Voting rights 5.11%). (Major shareholders as of 31st January, 2018)

Competitive Analysis of Sanofi

SWOT
PESTLE
The SWOT Analysis for Sanofi is presented below:
Strengths
Weaknesses
1. A global leader in healthcare
2. Consistently strong financial performance
3. Portfolio expansion through strategic acquisitions
1. Over dependence on Lantus and other flagship products
2. Major increase in other expenses
Opportunities
Threats
1. Potential in Vaccines
2. Growth opportunities in emerging markets
3. Use of digital technologies to improve R&D and clinical outcomes
1. Increasing availability of Counterfeit drugs
2. Threat from cheaper generic alternatives
3. Fierce competition with regards to market share
4. Increased transparency expectations leading to new regulations
5. Pricing pressures due to concentration of the US market
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Sanofi

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

1. Increasing availability of Counterfeit drugs: Counterfeit drugs is a growing menace especially in the emerging markets in Asia and Africa which is impacting major pharma players including Sanofi. Counterfeit Drugs affect Sanofi in two ways, first by decrease in sales due to low pricing and second by affecting the brand image of Sanofi, if counterfeit drug has any side-effects and below par performance.

2. Threat from cheaper generic alternatives: Branded pharmaceutical products lose their patents which pave the way for cheaper generic alternatives. This impacts the sales of the original brands in a major way. For example, Basaglar is generic drug of Lantus, from Eli Lilly and Boehringer Ingelheim Pharmaceuticals, whose price is approximately 15% less than of Lantus. Since its introduction in US 2016, Sanofi has lost revenue of €760 million from Lantus in 2017. In 2018, Mylan and Biocon have also secured EU approval for their their biosimilar for Sanofi’s Lantus which will further impact the company.

3. Fierce Competition: There is a huge competition among big pharma companies to capture the market share, the two-important factors that determine the winner is; the first mover in respective drug line, and complexity of manufacturing ground-breaking drug. An Example of this is U.S. Food and Drug Administration’s approval of two PCSK9 inhibitors, Repatha and Praluent from Amagen and Sanofi. Initially, the analyst estimated revenue of $6.1 billion for Praluent, but Sanofi has lost both first mover advantage and patent due to intense competition from Amagen and new product introduction by Pfizer in next two years, and analyst have revised their estimates.

4.Increased transparency expectations leading to new regulations: There are two types of transparency laws advocated by states in US; state price transparency laws and healthcare provider transparency laws. Both these laws impose obligations for price reporting, annual registration of sales representatives, and to submit details of payments made to HCPs by sales representatives. One of the impact with the new amendments is the pricing information of a drug will be available in public domain. This is also expected decrease the competitive advantage and lead to price capping by Government in cases of exorbitant pricing. Hence it would affect the revenue and profit margin of the company.

5. Pricing pressures due to concentration of the US market: The United States is one of the major markets for global drug makers. As the managed care organizations (MCOs) and pharmacy benefit managers (PBMs) are growing in size following major consolidation deals, pharma companies such as Sanofi are seen facing increased pricing pressure and usage negotiations. Despite a reduction in rates and increased negotiations, Sanofi suffered a setback in 2016 when CVS and UnitedHealthcare (UHG) announced that it would exclude Lantus/ Toujeo from commercial and MMC (Medicaid Managed Care) template. This would lead to increase in costs for Lantus/ Toujeo for patients under CVS and UHG, thus reducing its effective sales. Thus PBM and MCO concentration is likely to sustain and increase pricing pressures, negatively impacting Sanofi’s revenues margins.

Major Brands :

Pfizer, Merck, Bristol Myers-Squibb

Key Business Segments / Diversification :

Sanofi
Specialty Care Vaccines Diabetes & Cardiovascular Diseases
General Medicines & Emerging Markets (GEM) Consumer Healthcare (CHC)

Recent Acquisition / Mergers / Alliance / Joint Ventures / Divestitures :

Name
Business Segment
Year
Type
Objective/Synergy Achieved
BioverativHemophilia specialist2018Acquisition Will strengthen Sanofi’s presence in treatments for rare diseases
AblynxBiotechnology, nanobodies2018AcquisitionThe deal expands new Rare Blood Disorders franchise for Sanofi and strengthens its R&D platform
Source: Company website and other reliable sources. The detailed table is available in the Complete Report.
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Check out analysis of other relevant companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Sanofi Analysis Report

1.Integrated Report - https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/2017_Integrated_Report.pdf
2. Annual Report - https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/Annual_report_form_20F_2017.pdf
3. Insights - https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-road-to-digital-success-in-pharma
4. Economic affect pharmaceutical industry - https://bizfluent.com/list-6865506-economic-affect-pharmaceutical-industry-us-.html

Copyrights and Disclaimer

Sanofi SWOT and PESTLE analysis has been conducted by Pavankumar S and reviewed by senior analysts from Barakaat Consulting.

Copyright of Sanofi SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

Sanofi SWOT and PESTLE Analysis
Price : USD 12.53